目的 探討黃藤素分散片聯(lián)合替硝唑治療慢性盆腔炎的臨床療效。方法 選取2015年10月—2016年10月三門峽市中心醫(yī)院進(jìn)行治療的慢性盆腔炎患者92例，根據(jù)治療方案分為對(duì)照組（46例）和治療組（46例）。對(duì)照組靜脈滴注替硝唑氯化鈉注射液，1支/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服黃藤素分散片，4片/次，3次/d。兩組均連續(xù)治療2周。治療后，觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀評(píng)分、血清細(xì)胞因子水平及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.43%、97.82%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組血清腫瘤壞死因子-α（TNF-α）、單核細(xì)胞趨化蛋白-1（MCP-1）和可溶性細(xì)胞黏附因子-1（sICAM-1）水平均較治療前明顯降低，IL-4水平明顯增高，同組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述血清細(xì)胞因子水平顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者臨床癥狀評(píng)分均較治療前明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組臨床癥狀評(píng)分低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。兩組均無明顯不良反應(yīng)發(fā)生。結(jié)論 黃藤素分散片聯(lián)合替硝唑治療慢性盆腔炎效果顯著，可明顯改善患者臨床癥狀和細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Huangtengsu Dispersible Tablets combined with tinidazole in treatment of chronic pelvic inflammation. Methods Patients (92 cases) with chronic pelvic inflammation in Sanmenxia Central Hospital from October 2015 to October 2016 were randomly divided into control (46 cases) and treatment groups (46 cases), based on different treatments. Patients in the control group were iv administered with Tinidazole and Sodium Chloride Injection, one tube/time, twice daily. Patients in the treatment group were po administered with Huangtengsu Dispersible Tablets on the basis of control group, 4 tablets/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms scores, serum cytokine levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.43% and 97.82%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of TNF-α, MCP-1, and sICAM-1 in serum were significantly decreased, but IL-4 level was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, clinical symptoms scores in two groups were significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the clinical symptoms scores in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). There were no adverse reactions in two groups. Conclusion Huangtengsu Dispersible Tablets combined with tinidazole has a significant curative effect in treatment of chronic pelvic inflammation, can significantly improve the clinical symptoms and cytokines levels, which has a certain clinical application value.